“Access” usually arrives as a shopping question — where to buy, what is near me, which store ships. This cluster answers a different one. Access is a context: the law that governs a substance, the regulatory model that may or may not exist, and the supply chain that may or may not reach you. [1] primary-legal 21 U.S.C. § 812 — Schedules of controlled substances Link → A place changing its law does not create a store, and a product being available somewhere does not make it legal where you are, nor safe, nor effective. [2] Systematic review Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research doi:10.1177/02698811241254831 The whole cluster examines availability claims as claims, and reproduces none of the buying-guide framing found elsewhere.
Education-only orientation. This is not medical, dosing, sourcing, purchasing, or legal advice. It does not tell you where or how to obtain any substance. Decisions about any substance belong with a qualified clinician, and questions of legality belong with the law of your own jurisdiction.
What this page does and does not contain. It treats access as a legal, regulatory, and supply-chain context — a topic to understand, not a path to follow. It contains no vendor, store, marketplace, or brand names, no links to shops or checkouts, no prices, coupons, weights, or quantities, no shipping, delivery, or discreet-purchase instructions, no “where to buy”, “near me”, or “how to get it” pathways, no cultivation or spore-sourcing steps, and no claim that a substance being available anywhere makes it legal, safe, or effective for you. Every “where to buy” or “dispensary near me” claim found elsewhere is examined here as a claim about the landscape, never reproduced as instruction.
What “access” means here
In everyday microdosing talk, access is shorthand for a purchase: where to buy, which vendor ships, what is sold nearby. This cluster uses the word in its narrower, more honest sense — the legal, regulatory, and supply-chain conditions that determine whether a substance is lawfully obtainable at all, and through what channel. Those are questions about the landscape, not instructions for navigating it. Psilocybin remains a Schedule I controlled substance under U.S. federal law, a status that frames every availability claim regardless of what any local market appears to offer. [1] primary-legal 21 U.S.C. § 812 — Schedules of controlled substances Link →
The thesis: availability is not legality, safety, or efficacy
This is the direct sequel to the Formats cluster’s point that a delivery mechanism is not evidence. Here the claim is broader: the fact that something can be obtained tells you nothing about whether it is lawful for you, safe for you, or effective at all. The placebo-controlled evidence has not established a microdose effect in the first place, [2] Systematic review Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research doi:10.1177/02698811241254831 so no shop, supply route, or “availability” can convert an undemonstrated effect into a real one. Legality is settled by statute, not by a storefront; [3] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 safety is a clinical question; efficacy is a research question. Availability answers none of them.
The four distinctions, applied to access
| Distinction | An access claim that violates it | The honest reading |
|---|---|---|
| mechanism ≠ result | “It is sold here, so it must work” | A point of sale is a supply fact, not a measured outcome |
| full-dose ≠ microdose | “Available products are dosed for microdosing” | A product format is not evidence a sub-perceptual effect exists |
| reports ≠ outcomes | “Everyone near me is buying it” | Purchase volume is a market report, not an efficacy result |
| plausibility ≠ efficacy | “Lab-verified, shipped to you” | Verification of contents is plausible quality control, not demonstrated benefit |
What access can and cannot tell you
| Access can describe | Access cannot establish |
|---|---|
| The legal status that governs a substance in a place | That a substance is lawful for you to obtain or use |
| Whether a regulated supervised model exists | That a substance is safe to take |
| The gap between a policy change and an actual supply | That a substance produces a demonstrated effect |
| How purchase-oriented content is constructed | A reason to treat purchase as the next step |
A regulated, supervised access model — where one exists — is a legal and clinical arrangement, not a retail counter. [4] primary-legal Oregon Psilocybin Services (Ballot Measure 109; ORS Chapter 475A) Link → Examining it is description; advertising it would be something this site does not do.
The availability claim test
When any source says a substance is “available,” run the claim through these questions before letting it imply anything further. The point is not to act on the answers but to see how little a bare “available” actually establishes.
| Ask | Why it matters |
|---|---|
| Available where? | Availability is jurisdiction-specific; a claim true in one place is false in another |
| Available how? | Retail, a supervised service, a clinical trial, a religious pathway, and an informal market are different legal contexts |
| Available for what activity? | Possession, purchase, supervised administration, research, and sale carry different legal meanings |
| Available to whom? | Eligibility can depend on program rules, medical criteria, residency, age, or licensing |
| Verified by whom? | A seller’s claim is not an official legal or laboratory source |
| Answers safety, efficacy, or legality? | No — those require evidence, clinical judgement, and the statute that applies to you |
How this cluster routes everywhere else
Access touches the law, the science, and the supply chain but owns none of them. The law itself — decriminalization versus legalization, federal versus state, exemptions — lives in Legal Status and is referenced, not re-derived. The per-jurisdiction picture belongs to States & Cities. Whether microdosing produces an effect at all sits across Foundations and the evidence clusters. Sourcing risk to health — contamination, misidentification — is owned by Safety; identification and potency as research questions sit in Mushroom Intelligence. This page is the map; the articles that follow examine each access claim as a claim.
- Context, not a path
- Access describes the legal and supply landscape; it is not a route to purchase. [1] primary-legal 21 U.S.C. § 812 — Schedules of controlled substances Link →
- Availability ≠ legality
- A product being obtainable somewhere does not make it lawful where you are. [3] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
- Availability ≠ safety or efficacy
- No supply channel can validate an effect the controlled evidence has not shown. [2] Systematic review Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research doi:10.1177/02698811241254831
Frequently asked questions
Does this cluster tell me where to buy or how to get anything?
No. It treats access as a legal and supply-chain context to understand, not a route to follow. It names no vendor, links to no store, lists no price, and gives no sourcing, shipping, or cultivation steps. Where a substance is available is a separate question from whether it is lawful for you, and both are separate from whether it works. [1] primary-legal 21 U.S.C. § 812 — Schedules of controlled substances Link →
If something is available somewhere, does that make it legal for me?
No. Legality is set by the statute that applies where you are, not by a storefront or a shipment. [1] primary-legal 21 U.S.C. § 812 — Schedules of controlled substances Link → Psilocybin remains federally Schedule I in the United States, and a local market does not change that. The law itself is detailed in Legal Status.
Does availability mean a substance is safe or that it works?
No. Availability is a supply fact. Safety is a clinical question and efficacy is a research question. [2] Systematic review Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research doi:10.1177/02698811241254831 A product being obtainable, even one whose contents are verified, is plausible quality control — not demonstrated benefit. [3] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 This distinction has its own article: availability is not safety or efficacy.
How is this different from the version on the .net site?
The mirror pages are purchase funnels — they answer “where to buy” and “near me”, attach store links, and frame buying as the next step. This site reproduces none of that. It treats each of those as a claim about the legal and supply landscape to examine, not a step to follow. [4] primary-legal Oregon Psilocybin Services (Ballot Measure 109; ORS Chapter 475A) Link →